| Name | Title | Contact Details |
|---|
"With corporate headquarters in Los Gatos, BaySport, Inc. has been serving the Bay Area since 1984. The organization has evolved from providing ""on-site"" physical examination programs for corporations, to developing sports medicine centers with a strong"
Physicians Reimbursement Systs is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Curve Health is senior care without walls. Founded in April of 2020 on a platform that`s reduced patient transfers from Skilled Nursing Facilities (SNFs) to Emergency Departments by 50%+, Curve advances connected senior care by bridging the silos that hinder healthcare delivery today; enabling physicians to remotely care for patients in SNFs, at home, in ambulances or wherever they may be. Curve combines telemedicine, a health information exchange, predictive analytics and smart billing into a single platform, resulting in higher quality care + significant return on investment, while ensuring the most seamless patient experience.
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic
EnviroMerica is a Dublin, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.